Emmaus Life Sciences (Emmaus Life Sciences) Short Interest

View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Emmaus Life Sciences's Short Interest

For the Biotechnology subindustry, Emmaus Life Sciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Short Interest falls into.

Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503

Website

https://www.emmausmedical.com

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

Executives

Seah H. Lim	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee	director, officer: Vice Chairman & COO	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara	director, 10 percent owner, officer: Chairman and CEO	20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi	director	1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark	officer: SVP, Clinical Development	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich	officer: CIO & SVP	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood	director	956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii	officer: Chief Financial Officer	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato	director	3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran	officer: Chief Administrative Officer	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey	director	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki	officer: Sr. VP Finance	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501